

From: [REDACTED]
To: [REDACTED] (EMA); [REDACTED] (EMA)
Cc: Industry; [REDACTED] (EMA); [REDACTED] (EMA); RYS Andrzej Jan (SANTE); [REDACTED] (SANTE); [REDACTED] @emea.europa.eu; KYRIAKIDES Stella (CAB-KYRIAKIDES); BRETON Thierry (CAB-BRETON); LENARCIC Janez (CAB-LENARCIC); [REDACTED] GALLINA Sandra (SANTE); [REDACTED] (CAB-KYRIAKIDES); [REDACTED]
Subject: EFPIA COVID-19 Situational assessment to 29 January 2021
Date: vendredi 29 janvier 2021 15:31:40
Attachments: [COVID-19 EFPIA&VE Situational Assessment 29 January 2021.v02docx.docx](#)

Dear [REDACTED], dear [REDACTED]

Following your email of 25 January, please find attached, the brief summary of the information we collected from EFPIA and Vaccines Europe member companies on the supply of medicines.

As in the past, as we consider that the contents of the attached briefing is highly relevant to the Commission's work, I hope you won't mind if I took the initiative to copy this mail to the Commissioners and to DG SANTE colleagues.

Please do not hesitate to reach out if you have any questions.

Best wishes,

[REDACTED]

[REDACTED]

[REDACTED]

EFPIA - European Federation of Pharmaceutical Industries and Associations
Leopold Plaza Building
Rue du Trône 108
B-1050 Bruxelles

Tel: [REDACTED]
Tel: [+3226262555](tel:+3226262555) (Switchboard)
Email: [REDACTED] [@efpia.eu](mailto:[REDACTED]@efpia.eu)
www.efpia.eu



For more information related to COVID-19 see: <https://efpia.eu/news-events/the-efpia-view/statements-press-releases/european-pharmaceutical-industry-response-to-coronavirus/>